Article
Oncology
Qiuqiu Zhang, Qianwei Zhang, Huiyuan Li, Xiaofei Zhao, Han Zhang
Summary: Choroidal melanoma is commonly found in adults and lithium chloride has been shown to induce apoptosis in leukemia cells. In this study, lithium chloride was found to inhibit cell survival and clonogenic potential, induce apoptosis, and reduce proliferation of choroidal melanoma cells both in vitro and in vivo. The upregulation of NOXA and downregulation of Mcl-1 were identified as key factors in lithium chloride-induced apoptosis.
CANCER CELL INTERNATIONAL
(2021)
Article
Cell Biology
Sandra Weller, Astrid Toenniessen, Benjamin Schaefer, Tobias Beigl, Alina Muenchow, Kathrin Bopple, Ute Hofmann, Bernhard F. Gillissen, Walter E. Aulitzky, Hans-Georg Kopp, Frank Essmann
Summary: The BCL-2 inhibitor ABT-199 enhances its anti-tumor effect by blocking BCL-2 and inhibiting MCL-1 through the activation of NOXA. This finding suggests the potential of combining ABT-199 with other drugs for improved cancer treatment.
CELL DEATH DISCOVERY
(2022)
Article
Oncology
Azusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Akihiro Nishiyama, Kiyotaka Yoh, Takaya Ikeda, Naoki Furuya, Kazumi Nishino, Yuichiro Ohe, Koichi Goto, Seiji Yano
Summary: Concurrent TP53 mutations were found to reduce the efficacy of alectinib in ALK-rearranged NSCLC, while the combination of a proteasome inhibitor with alectinib showed promising results in inducing apoptosis in preclinical models, indicating a potential therapy for ALK-rearranged/TP53-mutated NSCLC.
CLINICAL CANCER RESEARCH
(2021)
Article
Cell Biology
Jingyi Zhang, Yuetong Wang, Chujie Yin, Ping Gong, Zhenwei Zhang, Linxiang Zhao, Samuel Waxman, Yongkui Jing
Summary: This study proposes a new triple combination for the treatment of AML by targeting the Noxa/Mcl-1/Bim axis to reverse the Mcl-1/p-Chk1 resistance of cytarabine therapy, using artesunate as a bridge to enhance the effects of venetoclax and cytarabine.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Sonia Nunez-Vazquez, Ismael Sanchez-Vera, Jose Saura-Esteller, Ana M. Cosialls, Anais F. M. Noisier, Fernando Albericio, Rodolfo Lavilla, Gabriel Pons, Daniel Iglesias-Serret, Joan Gil
Summary: Fluorizoline induces p53-independent apoptosis by targeting prohibitins and activating the ISR, leading to NOXA and apoptosis induction. ATF3 and ATF4 play crucial roles in fluorizoline-induced apoptosis, mediating the transcription of NOXA.
Article
Cell Biology
Ting Song, Na He, Ziqian Hao, Yunfan Yang
Summary: This study found that the gene ENKD1 is highly expressed in DLBCL and is associated with the growth and progression of the disease. Inhibiting ENKD1 induces apoptosis, suppresses cell proliferation, and blocks cell cycle progression in the G2/M phase of DLBCL cells. Furthermore, ENKD1 expression is positively correlated with the expression levels of several cellular homeostatic regulators, including the gene Sperm-associated antigen 5, which encodes an important mitotic regulator. These findings suggest that ENKD1 plays a critical role in regulating cellular homeostasis and may be a potential target for DLBCL treatment.
JOURNAL OF CELLULAR PHYSIOLOGY
(2023)
Article
Multidisciplinary Sciences
Mariana Belen Vera, Olivia Morris-Hanon, German Ignacio Nogueiras, Luisina Belen Ripari, Myrian Ines Esquivel, Carolina Perez-Castro, Leonardo Romorini, Gustavo Emilio Sevlever, Maria Elida Scassa, Guillermo Agustin Videla-Richardson
Summary: The recurrence of Glioblastoma is partly caused by resistant glioma stem cells. In this study, Bcl-xL and Mcl-1 were found to be crucial in regulating patient-derived glioma stem cell survival. Combining Bcl-xL inhibitors with chemotherapeutic agents can lead to increased cell death, and the sensitivity to Bcl-xL inhibition is correlated with Noxa expression levels.
SCIENTIFIC REPORTS
(2022)
Article
Cell Biology
Clara Alcon, Jorge Gomez Tejeda Zanudo, Reka Albert, Nikhil Wagle, Maurizio Scaltriti, Anthony Letai, Josep Samitier, Joan Montero
Summary: Breast cancer, the most frequent type of cancer in women, has seen improved treatment outcomes with the rapid development of therapeutic options, but some patients still relapse due to cancer cell acquired resistance. Research has identified the crucial role of anti-apoptotic proteins BCL-xL and MCL-1 in the resistance of ER+ breast cancer cells to therapy, leading to the proposal of sequential inhibition using BH3 mimetics as a new treatment option.
Article
Pharmacology & Pharmacy
Amineh Ghaderi, Wen Zhong, Mohammad Ali Okhovat, Johanna Aschan, Ann Svensson, Birgitta Sander, Johan Schultz, Thomas Olin, Anders Osterborg, Mohammad Hojjat-Farsangi, Hakan Mellstedt
Summary: The study evaluated the apoptotic effects of a small molecule inhibitor of ROR1 called KAN0441571C in human MCL cells, and found that KAN0441571C alone could induce apoptosis in MCL cells and showed synergistic effects when combined with other anti-tumor drugs. These results suggest that targeting ROR1 with KAN0441571C could be a potential therapeutic approach for MCL.
Article
Oncology
Francesca R. Di Cristofano, Mara W. Fong, Kelsey E. Huntington, Benedito A. Carneiro, Lanlan Zhou, Wafik S. El-Deiry
Summary: The combination of ONC201 and ABT-263 shows strong synergistic effects in inducing tumor cell death and altering cell death mediators. It is not toxic to human fibroblast cells and holds promise for further exploration in vivo and in clinical trials against various solid malignancies.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Hematology
Ana Domostegui, Suresh Peddigari, Carol A. Mercer, Flavia Iannizzotto, Marta L. Rodriguez, Marta Garcia-Cajide, Virginia Amador, Sarah T. Diepstraten, Gemma L. Kelly, Ramon Salazar, Sara C. Kozma, Eric P. Kusnadi, Jian Kang, Antonio Gentilella, Richard B. Pearson, George Thomas, Joffrey Pelletier
Summary: The study found that inhibition of ribosome biogenesis suppresses MYC-driven B-cell lymphomas, with a critical role played by the impaired RiBi checkpoint (IRBC). Additionally, the use of Actinomycin D (ActD) can significantly prolong the survival of lymphoma mice with normal p53 status.
Article
Biochemistry & Molecular Biology
Bruno Rafael Barboza, Sandra Maria de Oliveira Thomaz, Airton de Carvalho, Enilza Maria Espreafico, Jackson Gabriel Miyamoto, Alexandre Keiji Tashima, Mauricio Frota Camacho, Andre Zelanis, Maria Cristina Roque-Barreira, Thiago Aparecido da Silva
Summary: ArtinM, a lectin protein, binds to N-glycans on immune cell receptors and induces apoptosis in B cells derived from non-Hodgkin's lymphoma through its interaction with TLR2/CD14 N-glycans and CD3 gamma N-glycans. This cytotoxic effect is regulated by the phosphatase CD45 and the Src family protein kinases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Dermatology
Jose R. Cortes, Christina C. Patrone, Stuart Aidan Quinn, Yuhan Gu, Marta Sanchez-Martin, Adam Mackey, Anisha J. Cooke, Bobby B. Shih, Anouchka P. Laurent, Megan H. Trager, Adolfo A. Ferrando, Larisa J. Geskin, Teresa Palomero
Summary: The combination of romidepsin with mechlorethamine has shown synergistic antilymphoma effects in Se’zary syndrome, with downregulation of STAT5 phosphorylation being a key mediator of this interaction. Jak/STAT signaling plays a previously unrecognized role in the response to romidepsin and romidepsin-based combination therapies in Se' zary syndrome.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2021)
Article
Medicine, General & Internal
Urban Novak, Martin Fehr, Saemi Schaer, Martin Dreyling, Christian Schmidt, Enrico Derenzini, Thilo Zander, Georg Hess, Ulrich Mey, Simone Ferrero, Nicolas Mach, Carola Boccomini, Sebastian Boettcher, Michele Voegeli, Anne Cairoli, Vanesa-Sindi Ivanova, Thomas Menter, Stefan Dirnhofer, Bernhard Scheibe, Sandra Gadient, Katrin Eckhardt, Emanuele Zucca, Christoph Driessen, Christoph Renner
Summary: The combination of ibrutinib and bortezomib demonstrates durable efficacy in patients with relapsed or refractory MCL.
Article
Oncology
Gregoire Quinet, Wendy Xolalpa, Diana Reyes-Garau, Nuria Profitos-Peleja, Mikel Azkargorta, Laurie Ceccato, Maria Gonzalez-Santamarta, Maria Marsal, Jordi Andilla, Fabienne Aillet, Francesc Bosch, Felix Elortza, Pablo Loza-Alvarez, Brigitte Sola, Olivier Coux, Rune Matthiesen, Gael Roue, Manuel S. Rodriguez
Summary: The research identified an enrichment of autophagy-lysosome system (ALS) components in bortezomib (BTZ)-resistant cells in mantle cell lymphoma (MCL) patients. By blocking proteaphagy, the normal proteasomal activity was reactivated and the BTZ antitumor effect was restored in vitro and in vivo models of BTZ resistance. These findings suggest a proteolytic switch from the ubiquitin-proteasome system (UPS) to ALS in B-cell lymphoma refractory to proteasome inhibition, opening up new therapeutic avenues for treatment-resistant tumors.
Article
Biochemistry & Molecular Biology
Haruhito Totani, Keiko Shinjo, Miho Suzuki, Keisuke Katsushima, Shoko Mase, Ayako Masaki, Asahi Ito, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Takashi Ishida, Hiroshi Inagaki, Shinsuke Iida, Yutaka Kondo
Article
Hematology
Masato Saito, Toshihiko Ishii, Itaru Urakawa, Asuka Matsumoto, Ayako Masaki, Asahi Ito, Shigeru Kusumoto, Susumu Suzuki, Takeshi Takahashi, Akimichi Morita, Hiroshi Inagaki, Shinsuke Iida, Takashi Ishida
Article
Oncology
Yoshitaka Imaizumi, Masako Iwanaga, Kisato Nosaka, Kenji Ishitsuka, Kenichi Ishizawa, Shigeki Ito, Masahiro Amano, Takashi Ishida, Naokuni Uike, Atae Utsunomiya, Koichi Ohshima, Junji Tanaka, Yoshiki Tokura, Kensei Tobinai, Toshiki Watanabe, Kaoru Uchimaru, Kunihiro Tsukasaki
Article
Oncology
Ayako Masaki, Takashi Ishida, Yasuhiro Maeda, Asahi Ito, Susumu Suzuki, Tomoko Narita, Shiori Kinoshita, Takashi Yoshida, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Ryuzo Ueda, Ilseung Choi, Youko Suehiro, Shinsuke Iida
HEMATOLOGICAL ONCOLOGY
(2020)
Article
Hematology
Kentaro Yonekura, Shigeru Kusumoto, Ilseung Choi, Nobuaki Nakano, Asahi Ito, Youko Suehiro, Yoshitaka Imaizumi, Makoto Yoshimitsu, Kisato Nosaka, Eiichi Ohtsuka, Michihiro Hidaka, Tatsuro Jo, Hidenori Sasaki, Yukiyoshi Moriuchi, Masao Ogata, Hiro Tatetsu, Kenji Ishitsuka, Yasushi Miyazaki, Ryuzo Ueda, Atae Utsunomiya, Takashi Ishida
Article
Pathology
Keiichiro Fujii, Yuma Sakamoto, Ayako Masaki, Takayuki Murase, Yukie Tashiro, Kentaro Yonekura, Atae Utsunomiya, Asahi Ito, Shigeru Kusumoto, Shinsuke Iida, Ryuzo Ueda, Takashi Ishida, Hiroshi Inagaki
Summary: CCR4-C-IHC may be a useful tool for predicting response to mogamulizumab in ATL patients and screening for CCR4 mutation status.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2021)
Article
Hematology
Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Morishige Takeshita, Hiromi Iwasaki, Kentaro Yonekura, Yukie Tashiro, Asahi Ito, Shigeru Kusumoto, Atae Utsunomiya, Shinsuke Iida, Ryuzo Ueda, Hiroshi Inagaki
Summary: Studies have shown that alterations of the CD28 gene are closely related to patient age, prognosis, and subtype in adult T-cell leukaemia/lymphoma. Patients with CD28 gene alterations tend to have a worse prognosis, especially in chronic or smouldering ATL subtypes.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Morishige Takeshita, Reiji Muto, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano, Masahito Tokunaga, Kentaro Yonekura, Yukie Tashiro, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki
Summary: TP53 mutations are associated with unfavorable prognosis of ATL, regardless of treatment strategy. The establishment of alternative modalities to overcome the adverse impact of TP53 mutations in patients with ATL is required.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Kisato Nosaka, Shigeru Kusumoto, Nobuaki Nakano, Ilseung Choi, Makoto Yoshimitsu, Yoshitaka Imaizumi, Michihiro Hidaka, Hidenori Sasaki, Junya Makiyama, Eiichi Ohtsuka, Tatsuro Jo, Masao Ogata, Asahi Ito, Kentaro Yonekura, Hiro Tatetsu, Takeharu Kato, Toshiro Kawakita, Youko Suehiro, Kenji Ishitsuka, Shinsuke Iida, Takaji Matsutani, Atae Utsunomiya, Ryuzo Ueda, Takashi Ishida
Summary: The MIMOGA study showed that a lower percentage of CD2(-)CD19(+) B cells in PBMC was associated with unfavorable prognosis in patients with adult T-cell leukaemia-lymphoma. Analysis of IgG heavy-chain repertoire revealed a restricted repertoire in ATL patients compared to healthy individuals, with IgG diversity index correlating positively with B cell proportions. Higher serum soluble interleukin-2 receptor levels and lower IgG repertoire diversity were identified as significant factors affecting overall survival in patients. This study emphasizes the importance of humoral immune responses in patients undergoing mogamulizumab-containing treatment for ATL.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Morishige Takeshita, Hiromi Iwasaki, Kentaro Yonekura, Yukie Tashiro, Asahi Ito, Shigeru Kusumoto, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki
Summary: CD28 overexpression is associated with poor prognosis in ATLL patients, leading to a more aggressive clinical course. The infrequent overexpression of CD80/CD86 in ATLL is also noted.
Article
Hematology
Norio Tanaka, Seiichi Mori, Kazuma Kiyotani, Yuki Ota, Osamu Gotoh, Shigeru Kusumoto, Nobuaki Nakano, Youko Suehiro, Asahi Ito, Ilseung Choi, Eiichi Ohtsuka, Michihiro Hidaka, Kisato Nosaka, Makoto Yoshimitsu, Yoshitaka Imaizumi, Shinsuke Iida, Atae Utsunomiya, Tetsuo Noda, Hiroyoshi Nishikawa, Ryuzo Ueda, Takashi Ishida
Summary: By conducting molecular analysis on adult T-cell leukemia/lymphoma (ATL) patients, it was found that CCR4 alterations were associated with better clinical response and overall survival, while TP53, CD28, and CD274 alterations were associated with worse overall survival. This study contributes to the establishment of precision medicine using mogamulizumab in ATL patients.
Article
Oncology
Jolynn Zu Lin Ong, Rui Yokomori, Regina Wan Ju Wong, Tze King Tan, Ryuzo Ueda, Takashi Ishida, Shinsuke Iida, Takaomi Sanda
Summary: This study reveals that TP73 is highly activated under the control of a super-enhancer in ATL cells, contributing to cell proliferation and DNA damage response. Moreover, the deletion of TP73 exons 2-3 in primary ATL cases enhances cell proliferation and mutational burden.
Article
Oncology
Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Eiichi Ohtsuka, Morishige Takeshita, Reiji Muto, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano, Masahito Tokunaga, Kentaro Yonekura, Yukie Tashiro, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki
Summary: This study found that CCR7 gene alterations are significantly associated with survival rates in adult T-cell leukemia/lymphoma (ATL) patients receiving mogamulizumab treatment. However, CCR7 alterations have no significant impact on overall survival in the entire cohort or on patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, patients with CCR4 alterations but lacking CCR7 alterations have significantly better survival rates after receiving mogamulizumab-containing treatments.
HEMATOLOGICAL ONCOLOGY
(2022)
Letter
Hematology
Hiroaki Hiramatsu, Kisato Nosaka, Shigeru Kusumoto, Nobuaki Nakano, Ilseung Choi, Makoto Yoshimitsu, Yoshitaka Imaizumi, Michihiro Hidaka, Hidenori Sasaki, Junya Makiyama, Eiichi Ohtsuka, Tatsuro Jo, Masao Ogata, Asahi Ito, Kentaro Yonekura, Hiro Tatetsu, Takeharu Kato, Toshiro Kawakita, Youko Suehiro, Kenji Ishitsuka, Shinsuke Iida, Takaji Matsutani, Hiroyoshi Nishikawa, Atae Utsunomiya, Ryuzo Ueda, Takashi Ishida
Article
Oncology
Makoto Yoshimitsu, Kiyoshi Ando, Takashi Ishida, Shinichiro Yoshida, Ilseung Choi, Michihiro Hidaka, Yasushi Takamatsu, Mireille Gillings, Gloria T. Lee, Hiroshi Onogi, Kensei Tobinai
Summary: A phase I study in Japanese patients with non-Hodgkin's lymphoma demonstrated that HBI-8000 is well-tolerated and safe, with encouraging preliminary efficacy results.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)